Wednesday, April 2, 2025

Dairy #cattle #herds mount a characteristic #antibody response to highly pathogenic #H5N1 avian #influenza viruses

Abstract

An unprecedented outbreak of a highly pathogenic avian influenza virus, H5 clade 2.3.4.4b, was reported in United States dairy cattle during the spring of 2024. It has now spread to hundreds of herds across multiple states. In humans, antibodies to the hemagglutinin (HA) protein confer the strongest protection against infection. Human herd immunity limits viral spread but also drives the emergence of antigenic variants that escape dominant antibody responses. We used store-bought milk to profile the collective H5N1 antibody response of dairy cattle herds. We detected HA binding antibodies in specific samples from states with recent/ongoing outbreaks. These antibodies present in milk neutralized replicating virus expressing dairy cattle HA and neuraminidase (NA). Despite originating from independent vendors, dairies/plants, geographic regions, and time, antibodies present in these samples are remarkably similar in activity and HA binding specificity. The dominant antibody response was clade 2.3.4.4b HA specific, followed by cross-reactivity with other H5s. Whether the uniformity of the response is a pathway to achieve herd immunity or an avenue for antigenic variants to rapidly escape remains to be seen.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.04.01.646587v1

____

Highly pathogenic avian #influenza #management in high-density #poultry #farming areas

Abstract

The continuous spread of highly pathogenic avian influenza H5 viruses poses significant challenges, particularly in regions with high poultry farm densities where conventional control measures are less effective. Using phylogeographic and phylodynamic tools, we analysed virus spread in Southwestern France in 2020-21, a region with recurrent outbreaks. Following a single introduction, the virus spread regionally, mostly affecting duck farms, peaking in mid-December with a velocity of 27.8 km/week and an effective reproduction number between farms (Re) of 3.8, suggesting the virus can spread beyond current control radii. Transmission declined after late December following preventive culling. Farm infectiousness was estimated around 9 days. Duck farm density was the main driver of virus spread and we identified farm density and proximity thresholds required to maintain effective control (Re < 1). These findings offer actionable guidance to support regional biosecurity and to improve the robustness of the poultry sector to mitigate future outbreaks.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.03.25.645233v1

____

Tuesday, April 1, 2025

Intranasal #influenza virus-vectored #vaccine offers protection against clade 2.3.4.4b #H5N1 #infection in small animal #models

Abstract

The highly pathogenic avian influenza (HPAI) H5N1 virus has been endemic in aquatic birds since 1997, causing outbreaks in domestic poultry and occasional human infections worldwide. Recently, the cross-species transmission of a new reassortant variant from clade 2.3.4.4b of H5N1 to cattle in the US has heightened concerns regarding the expansion of host range and potential human infection. As eradicating the H5N1 virus from its reservoir is impossible, it is essential to prepare for a potential pandemic caused by an H5N1 derivative. Utilizing a deleted-NS1 live attenuated influenza viral vector vaccine system (DelNS1 LAIV), a system we have previously used in the development of a COVID-19 vaccine, we have rapidly developed an intranasal vaccine for cattle H5N1 and related clade 2.3.4.4b strains, based on publicly available sequences. Our research demonstrates that a single intranasal immunization can provide effective protection against lethal challenges from HPAI cattle or mink H5N1 variants, offering strong, sustained immunity after two months in female mouse and male hamster models. Immunogenicity analysis reveals that intranasal vaccination with DelNS1 LAIV induces robust neutralizing antibody, mucosal IgA and T cell responses in mice. It is crucial to further evaluate the DelNS1-H5N1 LAIV system to prepare for potential future H5N1 outbreaks in humans.

Source: Nature Communications, https://www.nature.com/articles/s41467-025-58504-z

____

#Denmark - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

On 31 March 2025 a clinical suspicion was reported to the Danish Veterinary and Food Administration. The affected poultry holding consists of 24 hens. On 1 April 2025 highly pathogenic avian influenza subtype H5N1 was confirmed by the national reference laboratory. A 3 km protection zone and a 10 km surveillance zone has been established. The culling was completed on 1 April 2025. Carcasses will be disposed of by rendering.

Source: WOAH, https://wahis.woah.org/#/in-review/6392

____


#India - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

 Death was observed in Guinea Fowl in Jharkhand State.

Source: WOAH, https://wahis.woah.org/#/in-review/6376

____


#India - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

House Crows in Bihar State.


_____

#PA and #PAX: two key #proteins from segment 3 of the #influenza viruses

Abstract

In recent years, the influenza viruses have posed an increasingly severe threat to public health. It is essential to analyze the virulence and pathogenesis of influenza viruses to prevent and control them, as well as create antiviral drugs. Previous studies have revealed that influenza virus segment 3 codes for not only the PA protein but also a novel protein, PA-X. PA protein is one subunit of the polymerase of influenza viruses and plays a critical role in its life cycle. PA presented endonuclease activity, the transcription and replication of the viral genome, viral virulence, protein degradation, and host immune response by interacting with viral proteins, including PB2, PB1, and host factors, including ANP32A, CHD6, HAX1, hCLE, HDAC6, MCM complex. PA mutations were involved in the viral replication, pathogenicity, and transmission of influenza viruses in poultry, mammals, and humans. PA-X is an open reading frame generated by +1 ribosomal code shift at the N-terminal amino acids of segment 3 and possesses the shutoff activity of host gene expression, regulating the host immune response, viral virulence and transmission. Therefore, PA is one ideal target for the development of antiviral drugs against influenza viruses. Baloxavir marboxil (BXM) and Favipiravir are two very effective anti-influenza virus drugs targeting the PA endonuclease domain of influenza A viruses. In this review, we summarized the structures, viral replication, virulent determinants and transmission, host factors, innate immunity, and antiviral drugs involved in PA and PA-X. The information is of great value for underlying the mechanism of viral replication and developing novel effective strategies to prevent and control influenza infection and the pandemic.

Source: Frontiers in Cellucal and Infection Microbiology, https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2025.1560250/full

____

Introducing a #framework for within-host #dynamics and #mutations modelling of #H5N1 #influenza infection in #humans

Abstract

Avian influenza A(H5N1) poses a public health risk due to its pandemic potential should the virus mutate to become human-to-human transmissible. To date, reported influenza A(H5N1) human cases have typically occurred in the lower respiratory tract with a high case fatality rate. There is prior evidence of some influenza A(H5N1) strains being a small number of amino acid mutations away from achieving droplet transmissibility, possibly allowing them to be spread between humans. We present a mechanistic within-host influenza A(H5N1) infection model, novel for its explicit consideration of the biological differences between the upper and lower respiratory tracts. We then estimate a distribution of viral lifespans and effective replication rates in human H5N1 influenza cases. By combining our within-host model with a viral mutation model, we determine the probability of an infected individual generating a droplet transmissible strain of influenza A(H5N1) through mutation. For three mutations, we found a peak probability of approximately 10(^-3) that a human case of H5N1 influenza produces at least one virion during the infectious period. Our findings provide insights into the risk of differing infectious pathways of influenza A(H5N1) (namely avian-human vs avian-mammal-human routes), demonstrating the three-mutation pathway being a cause of concern in human cases.

Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2024.09.01.24312235v3

____

Monday, March 31, 2025

#Population #Immunity to #HA Head, Stalk and #NA of HP Avian #Influenza 2.3.4.4b A(#H5N1) viruses in #USA and Impact of Seasonal Influenza on A(H5N1) Immunity

Abstract

The unprecedented 2.3.4.4b A(H5N1) outbreak in dairy cattle, poultry, and spillover to humans in the United States (US) poses a major public health threat. Population immunity is a critical component of influenza pandemic risk assessment. We conducted a comprehensive assessment of the population immunity to 2.3.4.4b A(H5N1) viruses and analyzed 1794 sera from 723 people (0.5-88 yrs) in multiple US geographic regions during 2021-2024. Low pre-existing neutralizing and hemagglutinin (HA) head binding antibodies and substantial cross reactive binding antibodies to N1 neuraminidase (NA) of 2.3.4.4b A(H5N1) were detected in US population. Antibodies to group 1 HA stalk were also prevalent with an age-related pattern. A(H1N1)pdm09 infection and influenza vaccination did not induce neutralizing antibodies but induced significant rise of NA inhibition (NAI) antibodies to N1 of 2.3.4.4b A(H5N1), and group 1 HA stalk antibodies. Understanding population susceptibility to novel influenza is essential for pandemic preparedness.

Source: MedRxIV, https://www.medrxiv.org/content/10.1101/2025.03.30.25323419v1

____

#Germany - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

 A poultry farm in Sachsen-Anhalt Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6378

____

#India - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Immediate notification

Backyard and Farmed Poultry in Karnataka State.

Source: WOAH, https://wahis.woah.org/#/in-review/6366

____

#Influenza at the #human - #animal #interface - #Summary and #risk #assessment, from 21 January to 19 March 2025 {WHO}



Influenza at the human-animal interface Summary and risk assessment, from 21 January to 19 March 2025{1} 


New human cases{2}: 

From 21 January to 19 March 2025, based on reporting date, the detection of influenza A(H5N1) in five humans, influenza A(H9N2) virus in four humans, influenza A(H1N1) variant ((H1N1)v) virus in one human, and influenza A(H1N2)v virus in one human were reported officially. 

Circulation of influenza viruses with zoonotic potential in animals: 

-- High pathogenicity avian influenza (HPAI) events in poultry and non-poultry continue to be reported to the World Organisation for Animal Health (WOAH).{3}  The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4} 

Risk assessment{5}: 

-- Sustained human to human transmission has not been reported from these events. Based on information available at the time of the risk assessment, the overall public health risk from currently known influenza viruses circulating at the human-animal interface has not changed remains low. The occurrence of sustained human-to-human transmission of these viruses is currently considered unlikely. Although human infections with viruses of animal origin are infrequent, they are not unexpected at the human-animal interface.  

Risk management

-- New candidate vaccine viruses (CVVs) for zoonotic influenza viruses for pandemic preparedness purposes were selected for development at the February 2025 WHO consultation on influenza vaccine composition for use in the northern hemisphere 2025-2026 influenza season. A detailed summary of zoonotic influenza viruses characterized since September 2024 is published here and updated CVVs lists are published here. 

IHR compliance

-- All human infections caused by a new influenza subtype are required to be reported under the International Health Regulations (IHR, 2005).{6} This includes any influenza A virus that has demonstrated the capacity to infect a human and its haemagglutinin gene (or protein) is not a mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human population. Information from these notifications is critical to inform risk assessments for influenza at the human-animal interface.


Avian influenza viruses in humans 

Current situation:  

Since the last risk assessment of 20 January 2025, one laboratory-confirmed human case of A(H5N1) infection was reported to WHO from Cambodia, one from the United Kingdom of Great Britain and Northern Ireland and three from the United States of America (USA).  

A(H5N1), Cambodia 

On 26 February 2025, Cambodia notified the WHO of a human case of influenza A(H5N1) in a boy from Prey Veng Province. The case had onset of fever, cough and fatigue on 17 February. He was initially seen at a local private clinic and given medication, but as his condition did not improve, he was transferred to Phnom Penh and hospitalized at a private hospital on 20 February. The case’s condition deteriorated, and he developed shortness of breath and was transferred on 24 February to a national hospital, which is a sentinel surveillance site for severe acute respiratory infection (SARI). Upon admission the case was isolated, nasopharyngeal (NP) and oropharyngeal (OP) swab specimens were collected and oseltamivir administered. On 25 February, the specimens tested positive for influenza A(H5N1) by reverse transcription-polymerase chain reaction (RT-PCR) at the National Institute of Public Health of Cambodia. The results were later confirmed by the Institut Pasteur du Cambodge (IPC) on 26 February. Sequence analysis of the HA gene revealed the virus belongs to clade 2.3.2.1e (previously classified as clade 2.3.2.1c){7}, and is similar to viruses circulating among birds, including poultry, and detected in human cases since late 2023 in Cambodia. The case was reported to have had exposure to sick and dead backyard chickens. Samples collected from the backyard chickens tested positive for A(H5N1). The case died on 25 February. No further cases were detected among the contacts of the case. This case is the second human infection with influenza A(H5N1) reported in Cambodia in 2025. 

A(H5N1), United Kingdom  

On 25 January 2025, the United Kingdom reported to WHO the detection of A(H5N1) in one individual in England who was sampled as part of a zoonotic influenza surveillance study launched by the UK Health Security Agency (UKHSA) in March 2023 to monitor people with close contact to infected birds. The individual was recruited to the surveillance study while working at a farm where birds were infected with A(H5N1) viruses and was found to be symptomatic. A sample collected on 23 January was confirmed A(H5)-positive at the national reference laboratory on 24 January. One symptomatic household contact tested negative. Sequencing of virus from the infected birds the case had contact with were determined to be of A(H5N1) clade 2.3.4.4b and the DI.2 genotype, which is prevalent within Europe at the current time. The DI.2 genotype is distinct from the A(H5) clade 2.3.4.4b genotypes that have been detected in North America.{8}  The UKHSA has previously notified WHO (in May, June, and July 2023) about four individuals who tested positive for influenza A(H5) virus as part of the UKHSA Zoonotic Influenza Surveillance Study.{9} 

A(H5N1), USA{10,11,12,13} 

In the USA, one laboratory-confirmed A(H5) infection was reported in an adult from the state of Ohio who worked at a commercial poultry facility where HPAI A(H5N1) virus had been detected in birds and was involved in depopulation activities. The individual had respiratory symptoms, was hospitalized, discharged and recovering at the time of the update. Genetic sequencing of the virus from this individual identified an avian influenza A(H5N1) virus from clade 2.3.4.4.b belonging to the genotype D1.3 genotype and no markers known that would impact the effectiveness of influenza antivirals or existing candidate vaccine viruses or changes associated with mammalian adaptation were identified.  Another laboratory-confirmed A(H5) infection was reported in an adult from the state of Wyoming who had direct contact with poultry infected with avian influenza A(H5) virus that died on their property. The individual was reported to have underlying health conditions that can be risk factors for severe influenza illness. This person has been discharged from the hospital and was recovering at the time of the update. Initial upper respiratory specimens were negative for influenza viruses; a lower respiratory specimen collected several days later in the hospital was positive for avian influenza A(H5N1) virus. Genetic sequencing of the virus from this individual identified an avian influenza A(H5N1) virus from clade 2.3.4.4.b belonging to the genotype D1.1, and the genetic mutation in the polymerase basic 2 (PB2) protein (E627K) that has previously been associated with more efficient virus replication in people and other mammals and has been detected in viruses from past human infections with A(H5) viruses.  Additionally, one laboratory-confirmed case was reported in an adult from the state of Nevada who worked at a commercial dairy cattle farm in an area where HPAI A(H5N1) viruses had been detected in cows. This individual developed conjunctivitis and recovered. Genetic sequencing of the virus from this individual identified an avian influenza A(H5N1) virus from clade 2.3.4.4.b also belonging to genotype D1.1, with a sequence nearly identical to that of the viruses that USDA reported from dairy cows in Nevada that the person worked with.{14} Sequencing also identified the D701N genetic mutation in the PB2 protein that has previously been associated with more efficient virus replication in mammalian cells and has been detected in viruses from past human infections with A(H5) viruses. Low pathogenicity and high pathogenicity avian influenza viruses have been detected in birds in the United States.  Since 2022, the HPAI A(H5) virus has been detected in commercial and backyard flocks in 48 states, impacting over 100 million birds. To date, 71 people have tested positive for A(H5) virus in the United States since 2022, with all but one of these cases occurring in 2024. All cases have been associated with exposure to either A(H5N1)-infected poultry or dairy cattle, except for two cases where the exposure source could not be identified.{15} To date, no human-to-human transmission of influenza A(H5) virus has been identified in the USA. A(H5N1) virus infections in dairy cattle and wild and domestic birds continue to be reported in the USA.{16} According to reports received by WOAH, various influenza A(H5) subtypes continue to be detected in wild and domestic birds in the Americas, Asia and Europe. Infections in non-human mammals are also reported, including in marine and land mammals.{17} A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{18}


Risk Assessment for avian influenza A(H5) viruses:  

1. What is the current global public health risk of additional human cases of infection with avian influenza A(H5) viruses?  

-- Most human cases so far have been infections in people exposed to A(H5) viruses, for example, through contact with infected poultry or contaminated environments, including live poultry markets, and occasionally infected mammals and contaminated environments. While the viruses continue to be detected in animals and related environments humans are exposed to, further human cases associated with such exposures are expected but unusual. The impact for public health if additional cases are detected is minimal. The current overall global public health risk of additional human cases is low. 

2. What is the likelihood of sustained human-to-human transmission of currently circulating avian influenza A(H5) viruses?  

-- No sustained human-to-human transmission has been identified associated with the recent reported human infections with avian influenza A(H5). There has been no reported human-to-human transmission of A(H5N1) viruses since 2007, although there may be gaps in investigations. In 2007 and the years prior, small clusters of A(H5) virus infections in humans were reported, including some involving health care workers, where limited human-to-human transmission could not be excluded; however, sustained human-to-human transmission was not reported.  Available evidence suggests that influenza A(H5) viruses circulating have not acquired the ability to efficiently transmit between people, therefore the likelihood of sustained human-to-human transmission is thus currently considered unlikely at this time.  

3. What is the likelihood of international spread of avian influenza A(H5) viruses by travellers?  

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. If this were to occur, further communitylevel spread is considered unlikely as current evidence suggests these viruses have not acquired the ability to transmit easily among humans.  


A(H9N2), China 

Since the last risk assessment of 20 January 2025, four human cases of infection with A(H9N2) influenza viruses were notified to WHO from China on 7 February 2025. All four cases were detected through the influenza-like illness (ILI) surveillance system. The cases were detected in Guangdong (one), Hunan (two) and Sichuan (one) provinces. One case, in an adult, had underlying conditions at the time of illness and was hospitalized with pneumonia. The other cases (two children and one adult) had mild illnesses. Each case had a known history of exposure to poultry prior to the onset of symptoms. Environmental samples collected from areas associated with two cases (live poultry markets) tested positive for influenza A(H9) virus while samples from the environments associated with the other two cases (backyard areas) tested negative. No further cases were detected among contacts of these cases and there was no epidemiological link between the cases.  


Risk Assessment for avian influenza A(H9N2):  

1. What is the global public health risk of additional human cases of infection with avian influenza A(H9N2) viruses?  

-- Most human cases follow exposure to the A(H9N2) virus through contact with infected poultry or contaminated environments. Most human infections of A(H9N2) to date have resulted in mild clinical illness in most cases. Nearly 130 human infections with A(H9N2) cases have been reported to date since 2003, and six of these have been severe or fatal and three of these were known to have underlying medical conditions. Since the virus is endemic in poultry in multiple continues in Africa and Asia{19}, further human cases associated with exposure to infected poultry are expected but remain unusual. The impact to public health if additional cases are detected is minimal. The overall global public health risk of additional human cases is low

2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H9N2) viruses?  

-- At the present time, no sustained human-to-human transmission has been identified associated with the event described above. Current evidence suggests that influenza A(H9N2) viruses from these cases have not acquired the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.  

3. What is the likelihood of international spread of avian influenza A(H9N2) virus by travellers?  

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. If this were to occur, further community level spread is considered unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired the ability to transmit easily among humans.  


Swine Influenza Viruses   

Current situation:    

Since the last risk assessment of 20 January 2025, one detection of an influenza A(H1N1)v virus was reported from China and one detection of an influenza A(H1N2)v was reported from the USA.  


Influenza A(H1N1)v, China 

On 7 February 2025, China notified WHO of a human case of Eurasian avian-like swine influenza A(H1N1) virus in a child from Yunnan Province. She developed mild upper respiratory tract symptoms on 12 November 2024 and a respiratory sample was collected on 13 November 2024 as part of routine influenza-like illness (ILI) surveillance. Close contacts remained asymptomatic and tested negative for influenza. She had exposure to backyard pigs however samples collected from the pigs tested negative for Eurasian avian-like swine influenza A(H1N1) viruses. The virus from this case was a clade 1C.2.3 virus. 


Influenza A(H1N2)v, USA  

A laboratory-confirmed human infection with an influenza A(H1N2)v virus was reported in an adult from the state of Iowa. The individual sought health care during the week ending 18 January 2025, was hospitalized, and recovered. An investigation by public health officials did not identify direct or indirect swine contact. No further cases were identified associated with this case. The virus from this case belonged to clade 1B.2.1 which is known to circulate in swine in the USA. 


Risk Assessment:   

1. What is the public health risk of additional human cases of infection with swine influenza viruses?    

-- Swine influenza viruses circulate in swine populations in many regions of the world. Depending on geographic location, the genetic characteristics of these viruses differ. Most human cases are exposed to swine influenza viruses through contact with infected animals or contaminated environments. Human infection tends to result in mild clinical illness in most cases. Since these viruses continue to be detected in swine populations, further human cases are expected but remain unusual. The impact for public health if additional cases are detected is minimal. The overall risk of additional human cases is low.    

2. What is the likelihood of sustained human-to-human transmission of swine influenza viruses?    

-- No sustained human-to-human transmission was identified associated with the events described above. Current evidence suggests that contemporary swine influenza viruses have not acquired the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.     

3. What is the likelihood of international spread of swine influenza viruses by travelers?    

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. If this were to occur, further community level spread is considered unlikely as current evidence suggest that these viruses have not acquired the ability to transmit easily among humans.   

For more information on zoonotic viruses, see the report from the WHO Consultation on the Composition of Influenza Virus Vaccines for Use in the 2025-2026 Northern Hemisphere Influenza Season held on 24-27 February 2025 at the following link: Antigenic and genetic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness in the 2025-2026 northern hemisphere influenza season.  


Overall risk management recommendations

Surveillance and investigations 

• Due to the constantly evolving nature of influenza viruses, WHO continues to stress the importance of global strategic surveillance in animals and humans to detect virologic, epidemiologic and clinical changes associated with circulating influenza viruses that may affect human (or animal) health. Continued vigilance is needed within affected and neighbouring areas to detect infections in animals and humans. Close collaboration with the animal health and environment sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. 

• As the extent of influenza virus circulation in animals is not clear, epidemiologic and virologic surveillance and the follow-up of suspected human cases should continue systematically. Guidance on investigation of non-seasonal influenza and other emerging acute respiratory diseases has been published on the WHO website. 

• Countries should increase avian influenza surveillance in domestic and wild birds, enhance surveillance for early detection in cattle populations in countries where HPAI is known to be circulating, include HPAI as a differential diagnosis in non-avian species, including cattle and other livestock populations, with high risk of exposure to HPAI viruses; monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in all animal species, including unusual hosts, to WOAH and other international organizations, share genetic sequences of avian influenza viruses in publicly available databases, implement preventive and early response measures to break the HPAI transmission cycle among animals through movement restrictions of infected livestock holdings and strict biosecurity measures in all holdings, employ good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals.{20}  

• When there has been human exposure to a known outbreak of an influenza A virus in domestic poultry, wild birds or other animals – or when there has been an identified human case of infection with such a virus – enhanced surveillance in potentially exposed human populations becomes necessary. Enhanced surveillance should consider the health care seeking behaviour of the population, and could include a range of active and passive health care and/or communitybased approaches, including: enhanced surveillance in local influenza-like illness (ILI)/SARI systems, active screening in hospitals and of groups that may be at higher occupational risk of exposure, and inclusion of other sources such as traditional healers, private practitioners and private diagnostic laboratories. 

• Vigilance for the emergence of novel influenza viruses of pandemic potential should be maintained at all times including during a non-influenza emergency. In the context of the cocirculation of SARS-CoV-2 and influenza viruses, WHO has updated and published practical guidance for integrated surveillance. Notifying WHO 

• All human infections caused by a new subtype of influenza virus are notifiable under the International Health Regulations (IHR, 2005).{21} State Parties to the IHR (2005) are required to immediately notify WHO of any laboratory-confirmed{22} case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic{23}. Evidence of illness is not required for this report. 

• WHO published the case definition for human infections with avian influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions. 


Virus sharing and risk assessment 

• It is critical that these influenza viruses from animals or from people are fully characterized in appropriate animal or human health influenza reference laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP) Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis{24} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk of pandemic influenza and to develop candidate vaccine viruses.  

• The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an in-depth assessment of risk associated with some zoonotic influenza viruses – notably the likelihood of the virus gaining human-to-human transmissibility, and the impact should the virus gain such transmissibility. TIPRA maps relative risk amongst viruses assessed using multiple elements. The results of TIPRA complement those of the risk assessment provided here, and those of prior TIPRA analyses will be published at http://www.who.int/teams/global-influenza-programme/avian-influenza/toolfor-influenza-pandemic-risk-assessment-(tipra).  


Risk reduction 

• Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should avoid contact with animals that are sick or dead from unknown causes, including wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.  

• Eggs, poultry meat and other poultry food products should be properly cooked and properly handled during food preparation. Due to the potential health risks to consumers, raw milk should be avoided. WHO advises consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption. 

• WHO has published practical interim guidance to reduce the risk of infection in people exposed to avian influenza viruses. 


Trade and travellers 

• WHO advises that travellers to countries with known outbreaks of animal influenza should avoid farms, contact with animals in live animal markets, entering areas where animals may be slaughtered, or contact with any surfaces that appear to be contaminated with animal excreta. Travelers should also wash their hands often with soap and water. All individuals should follow good food safety and hygiene practices.  

• WHO does not advise special traveller screening at points of entry or restrictions with regards to the current situation of influenza viruses at the human-animal interface. For recommendations on safe trade in animals and related products from countries affected by these influenza viruses, refer to WOAH guidance.  


Links:  

-- WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza 

-- WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic) 

-- WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2 

-- WHO Public health resource pack for countries experiencing outbreaks of influenza in animals:  https://www.who.int/publications/i/item/9789240076884 

-- Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO  https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus 

-- Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)virus 

-- World Organisation of Animal Health (WOAH) web page: Avian Influenza  https://www.woah.org/en/home/ 

-- Food and Agriculture Organization of the United Nations (FAO) webpage: Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/ 

-- OFFLU http://www.offlu.org/ 

____

{1} This summary and assessment covers information confirmed during this period and may include information received outside of this period. 

{2} For epidemiological and virological features of human infections with animal influenza viruses not reported in this assessment, see the reports on human cases of influenza at the human-animal interface published in the Weekly Epidemiological Record here.  

{3} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2. 

{4} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential. 

{5} World Health Organization (2012). Rapid risk assessment of acute public health events. World Health Organization. Available at: https://iris.who.int/handle/10665/70810. 

{6} World Health Organization. Case definitions for the 4 diseases requiring notification to WHO in all circumstances under the International Health Regulations (2005). Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).   

{7} Ort JT, Zolnoski SA, Lam TT, Neher R, Moncla LH. Development of avian influenza A(H5) virus datasets for Nextclade enables rapid and accurate clade assignment. bioRxiv [Preprint]. 2025 Feb 3:2025.01.07.631789. doi: 10.1101/2025.01.07.631789. PMID: 39829835; PMCID: PMC11741357. 

{8} UKHSA. Human case of avian flu detected in England, 27 January 2025. Available at: https://www.gov.uk/government/news/human-case-of-avian-flu-detected-in-england. 

{9} UKHSA. Investigation into the risk to human health of avian influenza (influenza A H5N1) in England: technical briefing 5, Updated 14 July 2023. Available at: https://www.gov.uk/government/publications/avian-influenzainfluenza-a-h5n1-technical-briefings/investigation-into-the-risk-to-human-health-of-avian-influenza-influenzaa-h5n1-in-england-technical-briefing-5. 

{10} US CDC. Weekly US Influenza Surveillance Report: Key Updates for Week 6, ending February 8, 2025. Available at: https://www.cdc.gov/fluview/surveillance/2025-week-06.html. 

{11} US CDC. Weekly US Influenza Surveillance Report: Key Updates for Week 7, ending February 15, 2025. Available at:  https://www.cdc.gov/fluview/surveillance/2025-week-07.html. 

{12} US CDC. CDC A(H5N1) Bird Flu Response Update, February 26, 2025. Available at: https://www.cdc.gov/birdflu/spotlights/h5n1-response-02262025.html. 

{13} US CDC. CDC A(H5N1) Bird Flu Response Update March 19, 2025. Available at https://www.cdc.gov/birdflu/spotlights/h5n1-response-03192025.html. 

{14} USDA. The Occurrence of Another Highly Pathogenic Avian Influenza (HPAI) Spillover from Wild Birds into Dairy Cattle. Available at:https://www.aphis.usda.gov/sites/default/files/dairy-cattle-hpaitech-brief.pdf 

{15} United States Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. Available at: https://www.cdc.gov/bird-flu/situationsummary/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fbird-flu%2Fphp%2Favian-flusummary%2Findex.html. 

{16}  United States Department of Agriculture. Highly Pathogenic Avian Influenza (HPAI) Detections in Livestock, 19 July 2024. Available at: https://www.aphis.usda.gov/livestock-poultry-disease/avian/avian-influenza/hpaidetections/livestock. 

{17}  World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2. 

{18} Food and Agriculture Organization of the United Nations. Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential/bird-species-affected-by-h5nx-hpai/en. 

{19} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential. 

{20} World Organisation for Animal Health. Statement on High Pathogenicity Avian Influenza in Cattle, 6 December 2024. Available at: https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/. 

{21} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).    

{22} World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza (2011). Available at: https://apps.who.int/iris/handle/10665/44518 

{23} World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits, 2nd edition. Available at: https://iris.who.int/handle/10665/341850 

{24} World Health Organization. Operational guidance on sharing influenza viruses with human pandemic potential (IVPP) under the Pandemic Influenza Preparedness (PIP) Framework (2017). Available at: https://apps.who.int/iris/handle/10665/25940 

Source: World Health Organization, https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment-19-march-2025

____

A #Human #H5N1 #Influenza Virus Expressing Bioluminescence for Evaluating Viral #Infection and Identifying #Therapeutic Interventions

Abstract

A multistate outbreak of highly pathogenic avian influenza virus (HPAIV) H5N1 in dairy cows was first reported on March 25, 2024, in the United States (US), marking the first discovery of HPAIV H5N1 in cattle. Soon after, a dairy worker on an affected dairy farm became the first human case linked directly to this outbreak. Studies with influenza A virus (IAV) require secondary methods to detect the virus in infected cells or animal models of infection. We modified the non-structural (NS) genome segment of the human A/Texas/37/2024 (HPhTX) H5N1 virus to create a recombinant virus expressing nanoluciferase (HPhTX NSs-Nluc), enabling the tracking of virus in cultured cells and mice via in vitro, ex vivo, and in vivo imaging systems (IVIS). In vitro, HPhTX NSs-Nluc showed growth and plaque characteristics similar to its wild-type (WT) counterpart. In vivo, HPhTX NSs-Nluc allowed tracking viral infection in the entire animals and in the organs of infected animals using in vivo and ex vivo IVIS, respectively. Importantly, the morbidity, mortality, and replication titers of HPhTX NSs-Nluc were comparable to those of the WT HPhTX. In vitro, HPhTX NSs-Nluc was inhibited by Baloxavir acid (BXA) to levels observed with WT HPhTX. We also demonstrate the feasibility of using HPhTX NSs-Nluc to evaluate the antiviral activity of BXA in vivo. Our findings support that HPhTX NSs-Nluc represents an excellent tool for tracking viral infections, including the identification of prophylactics or therapeutics for the treatment of the HPAIV H5N1 responsible of the outbreak in dairy cows.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.03.28.646035v1

____

A Live Attenuated #Vaccine Candidate against Emerging Highly Pathogenic #Cattle-Origin 2.3.4.4b #H5N1 Viruses

Abstract

Influenza viruses present a significant public health risk, causing substantial illness and death in humans each year. Seasonal flu vaccines must be updated regularly, and their effectiveness often decreases due to mismatches with circulating strains. Furthermore, inactivated vaccines do not provide protection against shifted influenza viruses that have the potential to cause a pandemic. The highly pathogenic avian influenza H5N1 clade 2.3.4.4b is prevalent among wild birds worldwide and is causing a multi-state outbreak affecting poultry and dairy cows in the United States (US) since March 2024. In this study, we have generated a NS1 deficient mutant of a low pathogenic version of the cattle-origin human influenza A/Texas/37/2024 H5N1, namely LPhTXdNS1, and validated its safety, immunogenicity, and protection efficacy in a prime vaccination regimen against wild-type (WT) A/Texas/37/2024 H5N1. The attenuation of LPhTXdNS1 in vitro was confirmed by its reduced replication in cultured cells and inability to control IFNβ promoter activation. In C57BL/6J mice, LPhTXdNS1 has reduced viral replication and pathogenicity compared to WT A/Texas/37/2024 H5N1. Notably, LPhTXdNS1 vaccinated mice exhibited high immunogenicity that reach its peak at weeks 3 and 4 post-immunization, leading to robust protection against subsequent lethal challenge with WT A/Texas/37/2024 H5N1. Altogether, we demonstrate that a single dose vaccination with LPhTXdNS1 is safe and able to induce protective immune responses against H5N1. Both safety profile and protection immunity suggest that LPhTXdNS1 holds promise as a potential solution to address the urgent need for an effective vaccine in the event of a pandemic for the treatment of infected animals and humans.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.03.28.646033v1

____

Sunday, March 30, 2025

Couple with Parrot, Pieter de Hooch (1668)

 


Public Domain.

Source: WikiArt, https://www.wikiart.org/en/pieter-de-hooch/couple-with-parrot-1668

____

#Coronavirus Disease Research #References (by AMEDEO, March 30 '25)

 


    Ann Intern Med

  1. GRANWEHR BP
    CBT and rehabilitation improved long COVID symptoms.
    Ann Intern Med. 2025;178:JC28.
    PubMed         Abstract available


    BMJ

  2. WISE J
    Covid-19: Inquiry hears of doctors' lack of confidence in PPE as ministers defend VIP lane.
    BMJ. 2025;388:r584.
    PubMed        


    Clin Infect Dis

  3. ALLAN-BLITZ LT, Klausner JD
    Shifting the Focus in Acute SARS-CoV-2 Management to Include Prevention of Long-COVID.
    Clin Infect Dis. 2025 Mar 26:ciaf158. doi: 10.1093.
    PubMed        


    Emerg Infect Dis

  4. SANDER B, Mishra S, Swayze S, Sahakyan Y, et al
    Population-Based Matched Cohort Study of COVID-19 Healthcare Costs, Ontario, Canada.
    Emerg Infect Dis. 2025;31:710-719.
    PubMed         Abstract available


    Intensive Care Med

  5. BIHLMAIER K, Willam C, Herbst L, Hackstein H, et al
    Rapid clinical effects of convalescent plasma therapy in severe COVID-19 acute respiratory distress syndrome (ARDS).
    Intensive Care Med. 2025 Mar 26. doi: 10.1007/s00134-025-07863.
    PubMed        


    J Infect

  6. JIN R, Qin T, Li P, Yuan J, et al
    Increased Circulation of Adenovirus in China During 2023-2024: Association with an Increased Prevalence of Species B and School-Associated Transmission.
    J Infect. 2025 Mar 21:106475. doi: 10.1016/j.jinf.2025.106475.
    PubMed         Abstract available

  7. CARSTENS G, Kozanli E, Bulsink K, McDonald S, et al
    Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in the Netherlands.
    J Infect. 2025 Mar 21:106474. doi: 10.1016/j.jinf.2025.106474.
    PubMed         Abstract available

  8. BING J, Huang Y, Du H, Guo P, et al
    Rapid spread of Candida auris in China after COVID-19.
    J Infect. 2025 Mar 21:106476. doi: 10.1016/j.jinf.2025.106476.
    PubMed        


    J Med Virol

  9. LARSEN TG, Ginty JR, Jessen R, Nielsen RB, et al
    Virus Monitoring in Denmark: A Community-Based Self-Sampling System to Surveil Respiratory Viruses and Associated Symptoms.
    J Med Virol. 2025;97:e70293.
    PubMed         Abstract available

  10. TACHIKAWA J, Aizawa Y, Watanabe K, Haino K, et al
    Sustained Maternal Antibodies Against Parechovirus-A3 During the Coronavirus Disease 2019 Pandemic.
    J Med Virol. 2025;97:e70313.
    PubMed         Abstract available


    J Virol

  11. NOETTGER S, Zech F, Nchioua R, Pastorio C, et al
    Role of N-linked glycosylation sites in human ACE2 in SARS-CoV-2 and hCoV-NL63 infection.
    J Virol. 2025 Mar 28:e0220224. doi: 10.1128/jvi.02202.
    PubMed         Abstract available

  12. JANA ID, Kanjo K, Roy S, Bhasin M, et al
    Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.
    J Virol. 2025 Mar 26:e0005125. doi: 10.1128/jvi.00051.
    PubMed         Abstract available

  13. ZHANG S, Cao Y, Huang Y, Zhang X, et al
    Abortive PDCoV infection triggers Wnt/beta-catenin pathway activation, enhancing intestinal stem cell self-renewal and promoting chicken resistance.
    J Virol. 2025 Mar 26:e0013725. doi: 10.1128/jvi.00137.
    PubMed         Abstract available

  14. LI P, Faraone JN, Hsu CC, Chamblee M, et al
    Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.
    J Virol. 2025 Mar 26:e0024225. doi: 10.1128/jvi.00242.
    PubMed         Abstract available

  15. JOHN K, Huntress I, Smith E, Chou H, et al
    Human long noncoding RNA VILMIR is induced by major respiratory viral infections and modulates the host interferon response.
    J Virol. 2025 Mar 25:e0014125. doi: 10.1128/jvi.00141.
    PubMed         Abstract available

  16. DADONAITE B, Burrell AR, Logue J, Chu HY, et al
    SARS-CoV-2 neutralizing antibody specificities differ dramatically between recently infected infants and immune-imprinted individuals.
    J Virol. 2025 Mar 25:e0010925. doi: 10.1128/jvi.00109.
    PubMed         Abstract available


    JAMA

  17. HANLON P, Butterly E, Wei L, Wightman H, et al
    Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.
    JAMA. 2025 Feb 3:e2427402. doi: 10.1001/jama.2024.27402.
    PubMed         Abstract available


    Nat Ment Health

  18. ATLAS LY, Farmer C, Shaw JS, Gibbons A, et al
    Dynamic effects of psychiatric vulnerability, loneliness and isolation on distress during the first year of the COVID-19 pandemic.
    Nat Ment Health. 2025;3:199-211.
    PubMed         Abstract available


    Nature

  19. KOZLOV M
    Exclusive: NIH to cut grants for COVID research, documents reveal.
    Nature. 2025 Mar 26. doi: 10.1038/d41586-025-00954.
    PubMed        

  20. VAN DAMME E, Abeywickrema P, Yin Y, Xie J, et al
    A small-molecule SARS-CoV-2 inhibitor targeting the membrane protein.
    Nature. 2025 Mar 26. doi: 10.1038/s41586-025-08651.
    PubMed         Abstract available

  21. WANG X, Huang Z, Xing L, Shang L, et al
    STING agonist-based ER-targeting molecules boost antigen cross-presentation.
    Nature. 2025 Mar 26. doi: 10.1038/s41586-025-08758.
    PubMed         Abstract available

  22. LAPORTE M, Jochmans D, Bardiot D, Desmarets L, et al
    A coronavirus assembly inhibitor that targets the viral membrane protein.
    Nature. 2025 Mar 26. doi: 10.1038/s41586-025-08773.
    PubMed         Abstract available


    Science

  23. COHEN J
    U.S. cuts hamper disease surveillance worldwide.
    Science. 2025;387:1336-1337.
    PubMed         Abstract available


    Travel Med Infect Dis

  24. PFAAR H, Lopez-Medina E, Escudero I, Hutagalung Y, et al
    Operational challenges and lessons learned from conducting febrile surveillance in a long-term randomized dengue vaccine trial in Latin America and Asia-Pacific.
    Travel Med Infect Dis. 2025 Mar 20:102840. doi: 10.1016/j.tmaid.2025.102840.
    PubMed         Abstract available

  25. BOGACKA A, Wroczynska A, Grzybek M
    Polish travellers on the move: a study of knowledge of travel health and associated practices among Polish travellers abroad.
    Travel Med Infect Dis. 2025 Mar 20:102842. doi: 10.1016/j.tmaid.2025.102842.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, March 30 '25)

 


    Ann Intern Med

  1. GRANWEHR BP
    CBT and rehabilitation improved long COVID symptoms.
    Ann Intern Med. 2025;178:JC28.
    PubMed         Abstract available

  2. IOANNOU GN, Berry K, Rajeevan N, Li Y, et al
    Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation.
    Ann Intern Med. 2025 Feb 4. doi: 10.7326/ANNALS-24-01015.
    PubMed         Abstract available


    Antiviral Res

  3. KUO YS, Chiang PC, Kuo CY, Huang CG, et al
    Inhibition of influenza A virus proliferation in mice via universal RNA interference.
    Antiviral Res. 2025 Mar 25:106149. doi: 10.1016/j.antiviral.2025.106149.
    PubMed         Abstract available


    Arch Virol

  4. YE QY, Jiang ZT, Jiang Y, Cai JW, et al
    Effectiveness of inactivated COVID-19 vaccine against symptom severity in hospitalized COVID-19 patients infected with the Omicron variant.
    Arch Virol. 2025;170:88.
    PubMed         Abstract available


    BMC Pediatr

  5. SHAN J, Yang X, Wang T
    Epidemiology of influenza from 2017 to 2022 in a national children's regional medical center.
    BMC Pediatr. 2025;25:240.
    PubMed         Abstract available

  6. WARNCKE K, Hofer SE, von Sengbusch S, Ermer U, et al
    Did smoking behavior change in adolescents and young adults with and without diabetes during the COVID-19 pandemic? A cohort study from the DPV registry.
    BMC Pediatr. 2025;25:236.
    PubMed         Abstract available


    Epidemiol Infect

  7. CHEN C, Chen D, Du Y, Jiang D, et al
    Global patterns and trends in deaths of influenza-associated lower respiratory infections from 1990 to 2019.
    Epidemiol Infect. 2025;153:e49.
    PubMed         Abstract available


    J Gen Virol

  8. HANKINSON J, Young D, Wignall-Fleming EB, Lukoszek R, et al
    The Cap-proximal secondary structures of the 5'UTRs of parainfluenza virus 5 mRNAs specify differential sensitivity to type I interferon and IFIT1.
    J Gen Virol. 2025;106.
    PubMed         Abstract available


    J Infect Dis

  9. CAO W, Su W, Song X, Ma L, et al
    Efficacy and Safety of WXSH0208 Tablets in Treatment of Acute Uncomplicated Influenza Infection in Adults: A Multicenter Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    J Infect Dis. 2025 Mar 25:jiaf075. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  10. KRAMMER F, Hermann E, Rasmussen AL
    Highly pathogenic avian influenza H5N1: history, current situation, and outlook.
    J Virol. 2025 Mar 27:e0220924. doi: 10.1128/jvi.02209.
    PubMed         Abstract available

  11. YU L, Jiang Y, Rang H, Wang X, et al
    Restriction of influenza A virus replication by host DCAF7-CRL4B axis.
    J Virol. 2025 Mar 27:e0013325. doi: 10.1128/jvi.00133.
    PubMed         Abstract available

  12. LANG Y, Shi L, Roy S, Gupta D, et al
    Detection of antibodies against influenza A viruses in cattle.
    J Virol. 2025 Mar 25:e0213824. doi: 10.1128/jvi.02138.
    PubMed         Abstract available


    Lancet

  13. WEISS DJ, Dzianach PA, Saddler A, Lubinda J, et al
    Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum and Plasmodium vivax malaria, 2000-22: a spatial and temporal modelling study.
    Lancet. 2025 Mar 5:S0140-6736(25)00038-8. doi: 10.1016/S0140-6736(25)00038.
    PubMed         Abstract available


    PLoS One

  14. YAN Z, Wang L
    The relationship between sleep disorder and mental health in athletes and its mediating role: a cross-sectional study.
    PLoS One. 2025;20:e0319813.
    PubMed         Abstract available

  15. ANDERSON D, Chapman J, Domingues J, Bobadilla G, et al
    The Healthy Minds, Thriving Kids Project: Educator perspectives on relevance and potential impact of a mental health skill building program.
    PLoS One. 2025;20:e0305450.
    PubMed         Abstract available

  16. SARKER MJA, Hasan M, Kabir A, Haque A, et al
    Leveraging artificial intelligence to assess the impact of COVID-19 on the teacher-student relationship in higher education.
    PLoS One. 2025;20:e0317567.
    PubMed         Abstract available

  17. FONSECA JFD, Silva SO, Silva LCMA, Camara RPPOA, et al
    Effect of the online module on leadership in knowledge acquisition among nursing students: A randomized controlled study protocol.
    PLoS One. 2025;20:e0320208.
    PubMed         Abstract available

  18. IMAI H, Suzuki J, Mizuno T, Takahashi S, et al
    The effect of antibiotic prescription in non-critically ill hospitalized patients with COVID-19: A Japanese inpatient database study.
    PLoS One. 2025;20:e0318803.
    PubMed         Abstract available

  19. ALKHARABSHEH A, Alshurafa S, Alhanbali S, Garadat S, et al
    Personal Listening device (PLD) usage among University Students and their audiometric profile during the shift to online learning post COVID-19.
    PLoS One. 2025;20:e0319665.
    PubMed         Abstract available

  20. TRUNG CTT, Dat NT, Teh CJ, Tee PK, et al
    Psychological capital and mental health problems among the unemployed in the post-COVID-19 era: Self- esteem as a moderator.
    PLoS One. 2025;20:e0319555.
    PubMed         Abstract available

  21. WATSON DL, Bonett S, Meanley S, Wood SM, et al
    Acceptability and feasibility of HIV self-testing integration into publicly-funded HIV prevention services: Perspectives from HIV testing agency staff that provide HIV testing services to sexual and gender minority youth in Philadelphia County.
    PLoS One. 2025;20:e0320290.
    PubMed         Abstract available

  22. LIN GSS, Tan WW, Chua KH, Kim JE, et al
    Adapting new norms: A mixed-method study exploring mental well-being challenges in dental technology education.
    PLoS One. 2025;20:e0320602.
    PubMed         Abstract available

  23. KODANI Y, Nagami S, Yokozeki A, Fukunaga S, et al
    Current status of Tele-speech language therapy by type and support for patients with post-stroke aphasia: A scoping review.
    PLoS One. 2025;20:e0319805.
    PubMed         Abstract available

  24. WEISE V, Buechl VCS, Mack JT, Garthus-Niegel S, et al
    Prospective associations between psychosocial work stress, work-privacy conflict, and relationship satisfaction of young parents during the COVID-19 pandemic: The mediating role of symptoms of depression and anger/hostility.
    PLoS One. 2025;20:e0320022.
    PubMed         Abstract available

  25. LIU J, Zhou K, Meng C, Liu Z, et al
    Roxadustat effectiveness versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study.
    PLoS One. 2025;20:e0320536.
    PubMed         Abstract available

  26. NIKBAKHT F, Heidarian Miri H, Mosafarkhani E, Sharifjafari F, et al
    Role of COVID-19 infection status on the prediction of future infection: Immunity or susceptibility.
    PLoS One. 2025;20:e0317959.
    PubMed         Abstract available

  27. MAKOANA KM, Naidoo CM, Zubair MS, Motshudi MC, et al
    Integration of metabolomics and chemometrics with in-silico and in-vitro approaches to unravel SARS-Cov-2 inhibitors from South African plants.
    PLoS One. 2025;20:e0320415.
    PubMed         Abstract available

  28. CHOI H, Marinescu I
    Work attendance anxiety, precarious work schedules, and job satisfaction of essential retail workers during the early COVID-19 pandemic.
    PLoS One. 2025;20:e0318586.
    PubMed         Abstract available

  29. SANTOS CVBD, Coelho LE, Goedert GT, Luz PM, et al
    Disability-adjusted life years associated with COVID-19 in Brazil, 2020.
    PLoS One. 2025;20:e0319941.
    PubMed         Abstract available

  30. DIABY M, Bangoura ST, Hounmenou CG, Kadio KJO, et al
    Exploratory analysis of poultry workers' knowledge and practices Regarding highly pathogenic avian influenza in Guinea.
    PLoS One. 2025;20:e0320890.
    PubMed         Abstract available

  31. MARTIN AF, Smith LE, Brooks SK, Stein MV, et al
    The impact of self-isolation on psychological wellbeing in adults and how to reduce it: A systematic review.
    PLoS One. 2025;20:e0310851.
    PubMed         Abstract available

  32. BIERRENBACH AL, Ranzani OT
    Evaluating the accuracy of ICD-10 codes for syncytial respiratory virus diagnosis in hospitalized patients: A record-linkage study (2022-2023).
    PLoS One. 2025;20:e0319436.
    PubMed         Abstract available

  33. PARK LS, Jaung R, Park JJ, Song C, et al
    Examining access to and trust in sources of COVID-19 information among CALD Asian communities in New Zealand.
    PLoS One. 2025;20:e0319326.
    PubMed         Abstract available


    Vaccine

  34. HARALAMBIEVA IH, Ratishvili T, Goergen KM, Grill DE, et al
    Effect of lymphocyte miRNA expression on influenza vaccine-induced immunity.
    Vaccine. 2025;55:127023.
    PubMed         Abstract available


    Virology

  35. RAHA JR, Kim KH, Tien Le CT, Bhatnagar N, et al
    A strategy of enhancing the protective efficacy of seasonal influenza vaccines by providing additional immunity to neuraminidase and M2e.
    Virology. 2025;606:110510.
    PubMed         Abstract available


    Virus Res

  36. MYERS ML, Conlon MT, Gallagher JR, Woolfork DD, et al
    Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric states.
    Virus Res. 2025 Mar 24:199563. doi: 10.1016/j.virusres.2025.199563.
    PubMed         Abstract available

Modeling the #impact of early #vaccination in an #influenza #pandemic in the #USA

Abstract

We modeled the impact of initiating one-dose influenza vaccination at 3 months vs 6 months after declaration of a pandemic over a 1-year timeframe in the US population. Three vaccine effectiveness (VE) and two pandemic severity levels were considered, using an epidemic curve based on typical seasonal influenza epidemics. Vaccination from 3 months with a high, moderate, or low effectiveness vaccine would prevent ~95%, 84%, or 38% deaths post-vaccination, respectively, compared with 21%, 18%, and 8%, respectively following vaccination at 6 months, irrespective of pandemic severity. While the pandemic curve would not be flattened from vaccination from 6 months, a moderate/high effectiveness vaccine could flatten the curve if administered from 3 months. Overall, speed of initiating a vaccination campaign is more important than VE in reducing the health impacts of an influenza pandemic. Preparedness strategies may be able to minimize future pandemic impacts by prioritizing rapid vaccine roll-out.

Source: npj Vaccines, https://www.nature.com/articles/s41541-025-01081-5

____

Saturday, March 29, 2025

#Molecular #epidemiology of #Kyasanur Forest Disease employing ONT-NGS a field forward #sequencing

Highlights

• The present analysis addresses the paucity of genetic information available for the recently emerged KFDV strains.

• As the virus is classified as a highly dangerous pathogen, it is essential to expand the existing genetic information.

• Continuous surveillance of the virus is essential for the development of a vaccine.

• The present study presents new findings on the KFD virus strains that were introduced into circulation in the period 2018-2020.

• The nanopore sequencing technology is presented as a proof of concept for the provision of early warnings in the field.


Abstract

The future of infectious agent detection and molecular characterization lies in field-forward, on-site strategies. The lack of genomic information for recently circulating Kyasanur Forest Disease virus strains is critical. Kyasanur Forest Virus Disease virus PCR-positive samples from 2018 to 2020 were selected for sequencing. Detailed molecular phylogenetic analyses were performed. In this study, we deciphered KFDV whole genomes using the ONT-NGS technique to analyze targeted KFD surveillance from 2018-2020. This study is the first to report recently circulating KFDV strains employing a simple on-site field-forward approach for viral surveillance. Altogether, 19 KFDV genomes were sequenced, and 28 non-synonymous variants were detected in the viral strains circulating from 2018-2020 in the Shivamogga district of Karnataka state in India. The prevailing Variant was detected in more than 10 changes in 80% of the samples in the viral envelope protein. Recently, circulating KFDV has been the predominant lineage over the past years. India reports seasonal outbreaks almost every year from the Karnataka state of the KFD. The genomic sequences deciphered here belong to the period (2018-2020) that covers the KFDV sequences as the first information. This will contribute to the development and revisiting of diagnostic and vaccine strategies.

Source: Journal of Clinical Virology, https://www.sciencedirect.com/science/article/abs/pii/S1386653225000253?dgcid=rss_sd_all

____

Heterogeneity across #mammalian- and #avian-origin A(#H1N1) #influenza viruses influences viral infectivity following incubation with host #bacteria from the human respiratory tract

Abstract

Influenza A viruses (IAV) are primarily transmitted between mammals by the respiratory route, and encounter bacteria in the respiratory tract before infecting susceptible epithelial cells. Previous studies have shown that mammalian-origin IAV can bind to the surface of different bacterial species and purified bacterial lipopolysaccharides (LPS), but despite the broad host range of IAV, few studies have included avian-origin IAV in these assessments. Since IAV that circulate in humans and birds are well-adapted to replication in the human respiratory and avian gastrointestinal tracts, respectively, we investigated the ability of multiple human and avian A(H1N1) IAV to associate with bacteria and their surface components isolated from both host niches. Binding interactions were assessed with microbial glycan microarrays, revealing that seasonal and avian IAV strains exhibited binding diversity to multiple bacterial glycans at the level of the virus and the bacterium, independent of sialic acid binding preference of the virus. Co-incubation of diverse IAV with LPS derived from Pseudomonas aeruginosa (P. aeruginosa), a respiratory tract bacterium, led to reduced retention of viral infectivity in a temperature dependent manner which was not observed when co-incubated with LPS from Escherichia coli, a gut bacterial isolate. Reduction of viral infectivity was supported by disruption of IAV virions following incubation with P. aeruginosa LPS using electron microscopy. Our findings highlight that both human and avian IAV can bind to bacterial surface components from different host sites resulting in differential functional interactions early after binding, suggesting the need to study IAV-bacteria interactions at the host range interface.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.03.28.645935v1

____

My New Space

Most Popular Posts